Zhu et al. [187] reported that while a dosing regimen of 1.0%/0.25% metformin was capable of reducing palpable mammary carcinoma incidence, multiplicity and tumor burden and prolonged latency, lower doses of metformin failed to inhibit carcinogenesis despite reducing plasma insulin. This evidence concerns the gene INS and neoplasm.